Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV005791898 | SCV006482790 | uncertain significance | Inborn genetic diseases | 2025-07-16 | criteria provided, single submitter | clinical testing | The c.3093-5C>T intronic alteration consists of a C to T substitution 5 nucleotides before coding exon 20 in the CACNA1A gene. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
| New York Genome Center | RCV002265814 | SCV002548748 | uncertain significance | Episodic ataxia type 2; Spinocerebellar ataxia type 6; Migraine, familial hemiplegic, 1; Developmental and epileptic encephalopathy, 42 | 2021-07-16 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV001462762 | SCV001666688 | likely benign | Episodic ataxia type 2; Developmental and epileptic encephalopathy, 42 | 2025-10-07 | criteria provided, single submitter | clinical testing | |
| Eurofins Ntd Llc |
RCV000593263 | SCV000704888 | uncertain significance | not provided | 2017-01-20 | criteria provided, single submitter | clinical testing |